7 March Washington
9:40 Development of a Novel Neuroprotective Molecule for Mild TBI/Concussion
In this presentation Mr. Glass will discuss the product development pathway for a neuroprotectant molecule from discovery through early-stage clinical trials. The presentation will cover discovery, pharmacology, oral formulation development, regulatory strategy and clinical trial considerations for NNZ-2566, a synthetic analog of the naturally occurring neuropeptide, IGF-1(1-3).
Larry Glass, Chief Executive Officer, Neuren Pharmaceuticals
7 March Washington9:40 Development of a Novel Neuroprotective...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.21 |
Change
-1.060(4.98%) |
Mkt cap ! $2.583B | |||
| Open | High | Low | Value | Volume |
| $20.98 | $21.06 | $20.14 | $6.308M | 308.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3926 | $20.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.21 | 388 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |